vs
Side-by-side financial comparison of Huntington Ingalls Industries (HII) and Organon & Co. (OGN). Click either name above to swap in a different company.
Huntington Ingalls Industries is the larger business by last-quarter revenue ($1.7B vs $1.5B, roughly 1.1× Organon & Co.). Organon & Co. runs the higher net margin — 10.0% vs 8.9%, a 1.1% gap on every dollar of revenue. On growth, Huntington Ingalls Industries posted the faster year-over-year revenue change (13.8% vs -3.5%). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-4.7% CAGR vs -25.2%).
Huntington Ingalls Industries, Inc. (HII) is the largest military shipbuilding company in the United States as well as a provider of professional services to partners in government and industry. HII was formed on 31 March 2011, as a divestiture from Northrop Grumman.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
HII vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $1.5B |
| Net Profit | $149.0M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 9.3% | — |
| Net Margin | 8.9% | 10.0% |
| Revenue YoY | 13.8% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $3.79 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.7B | $1.5B | ||
| Q4 25 | $3.5B | $1.5B | ||
| Q3 25 | $3.2B | $1.6B | ||
| Q2 25 | $3.1B | $1.6B | ||
| Q1 25 | $2.7B | $1.5B | ||
| Q4 24 | $3.0B | $1.6B | ||
| Q3 24 | $2.7B | $1.6B | ||
| Q2 24 | $3.0B | $1.6B |
| Q1 26 | $149.0M | $146.0M | ||
| Q4 25 | $159.0M | $-205.0M | ||
| Q3 25 | $145.0M | $160.0M | ||
| Q2 25 | $152.0M | $145.0M | ||
| Q1 25 | $149.0M | $87.0M | ||
| Q4 24 | $123.0M | $109.0M | ||
| Q3 24 | $101.0M | $359.0M | ||
| Q2 24 | $173.0M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | 9.3% | — | ||
| Q4 25 | 4.9% | -9.8% | ||
| Q3 25 | 5.0% | 15.2% | ||
| Q2 25 | 5.3% | 14.4% | ||
| Q1 25 | 5.9% | 6.7% | ||
| Q4 24 | 3.7% | 8.1% | ||
| Q3 24 | 3.0% | 13.1% | ||
| Q2 24 | 6.3% | 14.6% |
| Q1 26 | 8.9% | 10.0% | ||
| Q4 25 | 4.6% | -13.6% | ||
| Q3 25 | 4.5% | 10.0% | ||
| Q2 25 | 4.9% | 9.1% | ||
| Q1 25 | 5.4% | 5.8% | ||
| Q4 24 | 4.1% | 6.8% | ||
| Q3 24 | 3.7% | 22.7% | ||
| Q2 24 | 5.8% | 12.1% |
| Q1 26 | $3.79 | $0.55 | ||
| Q4 25 | $4.06 | $-0.78 | ||
| Q3 25 | $3.68 | $0.61 | ||
| Q2 25 | $3.86 | $0.56 | ||
| Q1 25 | $3.79 | $0.33 | ||
| Q4 24 | $3.15 | $0.42 | ||
| Q3 24 | $2.56 | $1.38 | ||
| Q2 24 | $4.38 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $216.0M | — |
| Total DebtLower is stronger | $2.7B | — |
| Stockholders' EquityBook value | $5.1B | — |
| Total Assets | $12.5B | — |
| Debt / EquityLower = less leverage | 0.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $216.0M | — | ||
| Q4 25 | — | $574.0M | ||
| Q3 25 | — | $672.0M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | — | $675.0M | ||
| Q3 24 | — | $763.0M | ||
| Q2 24 | — | $704.0M |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | $2.7B | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.1B | $752.0M | ||
| Q3 25 | $5.0B | $906.0M | ||
| Q2 25 | $4.9B | $733.0M | ||
| Q1 25 | $4.8B | $542.0M | ||
| Q4 24 | $4.7B | $472.0M | ||
| Q3 24 | $4.2B | $493.0M | ||
| Q2 24 | $4.2B | $144.0M |
| Q1 26 | $12.5B | — | ||
| Q4 25 | $12.7B | $12.9B | ||
| Q3 25 | $12.3B | $13.6B | ||
| Q2 25 | $12.1B | $13.5B | ||
| Q1 25 | $12.1B | $13.2B | ||
| Q4 24 | $12.1B | $13.1B | ||
| Q3 24 | $11.1B | $12.8B | ||
| Q2 24 | $11.3B | $12.2B |
| Q1 26 | 0.52× | — | ||
| Q4 25 | 0.53× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | 0.58× | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-390.0M | — |
| Free Cash FlowOCF − Capex | $-461.0M | — |
| FCF MarginFCF / Revenue | -27.7% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | -2.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $795.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-390.0M | — | ||
| Q4 25 | $650.0M | $141.0M | ||
| Q3 25 | $118.0M | $264.0M | ||
| Q2 25 | $823.0M | $220.0M | ||
| Q1 25 | $-395.0M | $75.0M | ||
| Q4 24 | $391.0M | $390.0M | ||
| Q3 24 | $213.0M | $141.0M | ||
| Q2 24 | $-9.0M | $332.0M |
| Q1 26 | $-461.0M | — | ||
| Q4 25 | $516.0M | $96.0M | ||
| Q3 25 | $13.0M | $218.0M | ||
| Q2 25 | $727.0M | $181.0M | ||
| Q1 25 | $-462.0M | $43.0M | ||
| Q4 24 | $277.0M | $335.0M | ||
| Q3 24 | $125.0M | $99.0M | ||
| Q2 24 | $-99.0M | $300.0M |
| Q1 26 | -27.7% | — | ||
| Q4 25 | 14.8% | 6.4% | ||
| Q3 25 | 0.4% | 13.6% | ||
| Q2 25 | 23.6% | 11.4% | ||
| Q1 25 | -16.9% | 2.8% | ||
| Q4 24 | 9.2% | 21.0% | ||
| Q3 24 | 4.5% | 6.3% | ||
| Q2 24 | -3.3% | 18.7% |
| Q1 26 | 4.4% | — | ||
| Q4 25 | 3.9% | 3.0% | ||
| Q3 25 | 3.3% | 2.9% | ||
| Q2 25 | 3.1% | 2.4% | ||
| Q1 25 | 2.5% | 2.1% | ||
| Q4 24 | 3.8% | 3.5% | ||
| Q3 24 | 3.2% | 2.7% | ||
| Q2 24 | 3.0% | 2.0% |
| Q1 26 | -2.62× | — | ||
| Q4 25 | 4.09× | — | ||
| Q3 25 | 0.81× | 1.65× | ||
| Q2 25 | 5.41× | 1.52× | ||
| Q1 25 | -2.65× | 0.86× | ||
| Q4 24 | 3.18× | 3.58× | ||
| Q3 24 | 2.11× | 0.39× | ||
| Q2 24 | -0.05× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HII
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
